As of December 31, 2022, the company’s cash, cash equivalents, and restricted cash was $24.8M. Total operating expenses for the fourth quarter and year ended December 31, 2022 were $10.9M and $40.8M, respectively John Bencich, CEO of Achieve, commented, "We believe that cytisinicline has the potential to help millions of people overcome their dependence to nicotine, and ultimately, live better and healthier lives. We will continue to honor our commitment to the patients we serve, and the numerous stakeholders who share our confidence in cytisinicline, by delivering on our key milestones in the year ahead. We look forward to 2023 being the most pivotal and exciting year yet for Achieve."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ACHV:
- Achieve Life Sciences Announces Granting of New Hire Inducement Award
- Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2022 and Provides Corporate Update
- Achieve Life Sciences Announces Last Subject Last Visit Completed in Phase 2 ORCA-V1 Trial of Cytisinicline for e-Cigarette Cessation
- Achieve Life announce last subject last visit complete in Phase 2 ORCA-V1 trial
- Achieve Life Sciences Announces Presentation of the Phase 3 ORCA-2 Trial of Cytisinicline at Society for Research on Nicotine and Tobacco (SRNT) Annual Meeting
